Skip to main content

Table 1 Studying demographic data, liver, and renal profile among studied groups

From: The role of IL-4 gene polymorphism in HCV-related hepatocellular carcinoma in Egyptian patients

 

Control

(n = 30)

Cirrhosis

(n = 40)

HCC

(n = 50)

p value

Age (years)

 Median (range)

50.00 (40.00–59.00)

52.5 (43.00–66.00)

52.5 (42.00–67.00)

0.066

Gender

 Male (n, %)

 Female (n, %)

16 (53.3)

14 (46.7)

22 (55.0)

18 (45.0)

32 (64.0)

18 (36.0)

0.562

ALT (U/L)

Median (range)

17.00 (9.0–36.0)

48.50 (16.0–146.0)

55.50 (20.0–102.0)

< 0.001 a,b

AST (U/L)

 Median (range)

19.00 (9.0–36.0)

60.50 (16.0–146.0)

62.50 (20.0–102.0)

< 0.001 a,b

Total bilirubin (mg/dL)

 Median (range)

0.50 (0.10–0.80)

1.19 (0.45–4.18)

1.50 (0.73–3.63)

< 0.001 a,b

Direct bilirubin (mg/dL)

 Median (range)

0.10 (0.07–0.23)

0.38 (0.09–3.08)

0.62 (0.18–2.53)

< 0.001 a,b

Albumin (g/dL)

 Median (range)

4.40 (3.50–5.10)

3.68 (2.20–4.90)

3.32 (2.20–4.52)

< 0.001 a,b

Urea (mg/dL)

 Median (range)

27.50 (17.0–41.0)

37.50 (22.0–56.0)

38.00 (22.0–67.0)

< 0.001 a,b

Creatinine (mg/dL)

 Median (range)

0.80 (0.50–1.20)

0.87 (0.58–1.50)

1.00 (0.50–1.50)

0.001 a,b

  1. ALT alanine aminotransferase, AST aspartate aminotransferase
  2. Data are median and range in parenthesis, otherwise are n (%)
  3. Significant p value < 0.05
  4. aOn comparing a control and cirrhotic patients
  5. bControl and HCC patients
  6. cCirrhotic and HCC patients